An effect of metrizamide, a contrast medium, on results of f3-endorphin radioimmunoassay was examined. We found that 1, 5, and 10 L of the medium added to 100 p.L of standard containing 0 to 500 pg of 13-endorphin shifted the standard curve to the left in proportion to the metrizamide concentration. Three other contrast media showed a similar effect at low concentrations of /3-endorphin. This effect of contrast media artificially increased results in radioimmunoassay of /3-endorphin in cerebrospirial fluid, the mean overestimate being 121.9% (range, 0 to 435%). For plasma samples, this effect of contrast media resulted in an average 11.7% overestimate of /3-endorphin (range, -16% to 41%). These observations bring into question the validity of a previous suggestion that an increase in 3-endorphin in cerebrospinal fluid after intracerebral electrical stimulation is the mechanism for stimulation-produced analgesia.
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Electrical stimulation of the periventricular gray area has been reported to relieve pain effectively (1-3). Evidence suggesting that this effect is mediated via the opiate system includes the observation that /3-endorphin concentrations in human cerebrospinal fluid (CSF) increase after analgesic 
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and Obrador (6) reported no statistically significant increases in CSF f3-endorphin as measured by a radioreceptor assay method after stimulation-produced analgesia of the periventricular gray area. We also have utilized stimulation-produced analgesia for relief of chronic pain in patients and have examined the effect of electrical stimulation of the brain on CSF (3-endorphin. Although we observed apparent increases in CSF f3-endorphin, our use of a more frequent sampling technique has produced results that lead to a different conclusion than that suggested previously (4, 5). We have observed that the increase in apparent CSF (3-endorphin is concurrent with the infusion of contrast medium prior to initiation of stimulation (7). Moreover, we found a contrastinduced increase in immunoreactive f3-endorphin in human lumbar CSF after routine metrizamide myelography (8). These results clearly indicate that it is some effect of the contrast medium, not electrical stimulation of the brain, that is responsible for the apparent increases in CSF /3-endorphin immunoreactivity.
One possible mechanism through which the contrast medium could produce this effect is a nonspecific interference with the immunoreactiv-'Endocrinology Laboratory, Department of Medicine, and 2[) partment of Surgery (Neurosurgery), the University of Chicago Pritzker School of Medicine, Chicago, IL 60637.
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ity of f3-endorphin in a radioimmunoassay system, commonly known as "matrix effect." To determine whether sample matrices containing contrast medium would affect the assay results, we carried out the present in vitro studies. The /3-endorphin standard and tracer and a rabbit antiserum to (3-endorphin were purchased as a kit from New England Nuclear, Boston, MA 02118. According to the supplier's description, the antiserum is specific for /3-endorphin with <0.10% cross reactivity with other endorphins, enkephalins, or a-melanotropin. However, it cross reacts by 50% with /3-lipotropin, a pituitary peptide, residues 61 to 91 of which are identical to those in the 13-endorphin molecule.
Materials and Methods
To obviate any adsorption of /3-endorphin onbo glass surface, we used Falcon no. 2038 plastic tubes in testing competitive binding of /3-endorphin. The assay buffer was 0.1 mol/L phosphate, pH 6.0, containing 0.05 mol of NaCl and 1 g of gelatin per liter. For equilibrium incubation, we mixed an increasing amount of standard (from 0 to 500 pg in 100 L per tube), a fixed amount of tracer (10 000 to 20 000 cpm in 100 ML), and a fixed volume of antiserum appropriately diluted in 100 L. An alternative, non-equilibrium procedure was overnight incubation of the standard and antiserum solutions before the tracer was added. After two days of incubation at 4#{176}C, we separated free hormone from bound by adding a diluted dextran-charcoal mixture (0.5 mL of the phosphate buffer containing, per liter, 16 g of Norit A charcoal, 1.6 g of dextran T-70, 0.05 mol of NaC1, 1 g of gelatin, and 5 mmol of EDTA) or a goat anti-rabbit yglobulin serum (50 L) before centrifugation. We tested the possible procedural influence on assay results with or without contrast media by combining the two incubation conditions with the two methods of separation. The radioactivity in each tube was counted before and after the separation in a refrigerated counter (Packard Auto-Gamma Scintillation Spectrometer, Model 5160). A specific boundltotal radioactivity ratio in percentage (SB%) was calculated from each standard concentration and was corrected to obtain a net percentage binding, B(%), by subtracting the nonspecific We tested the matrix effect of contrast media on CSF and plasma /3-endorphin immunoreactivity in control CSF from seven patients who were scheduled for myelography. CSF samples were drawn before contrast medium was administered. Plasma samples were also collected from four normal volunteers before and after an insulin tolerance test. Insulin injection stimulates the release of several anterior pituitary hormones, including /3-endorphin (our own unpublished data). For visualization of the periventricular gray area, 2 to 6 mL of a metrizamide solution (6.75 g in 50 mL) was injected. Human ventricular CSF volume is less than 23 mL in adults, so we estimated the concentration of metrizamide in CSF specimens collected after injection to be 10.8 to 27.9 g/L. In our in vitro testing, we added 0, 2, 5, and 10 4 of a concentrated metrizamide solution (6.75 g in 15 mL) and sufficient quantity of buffer to 110 4 of CSF (or plasma) sample to make up the final volume of 100 4. The corresponding metrizamide concentrations in these samples were 0, 9, 22.5, and 40.5 g/L. The rest of the procedure was identical to the above steps for competitive binding study with /3-endorphin standard.
Results
During the two-month period from the time when a fresh kit was used to the expiration date of the kit, B(%) values for the zero-standard tube progressively declined by 25%-from 55% to 30%. The antiserum and standard solutions were stable for two months. Thus it was the deterioration of tracer causing the reduction of binding performance.
In spite of the declining B(%) values, results for quality-control samples were unaltered in repeated assays. The different time schedules of incubation and methods for separating the free and the bound hormone did not affect the performance of assay materials; results for quality-control samples remained unchanged. A plot of log standard dose vs binding gave a sigmoid curve, indicating a characteristic competition between /3-endorphin standard and tracer to bind the antibody. Within a single assay, the average B(%) values for all concentrations of standard varied by <2.1% of the means in six repeated tubes.
As shown in Figure 1 , metrizamide lowered the B(%) values of /3-endorphin immunoreactivity at each standard concentration, an effect that was more pronounced at low concentrations of /3-endorphin. The magnitude of the decrease in B(%) was related to the amount of metrizamide present in the system. Below 50 pg of /3-endorphin per tube, 2 4 of metrizamide solution decreased the original B(%) means by an average of 1.7%, whereas 5 and 10 4 decreased them by 7.0 and 12.3%, respectively. This effect of metrizamide on the /3-endorphin standard curve was demonstrable regardless of the procedure used in the binding experiments.
The other three contrast media (10 4 per tube) also decreased the B(%) values and shifted the (3-endorphin standard curve to the left (Figure 2 ), but this effect was greatest with metrizamide, followed by iothalamate, diatrizoate, and iophendylate, in that order.
Addition of contrast medium to CSF samples in vitro also distorted f3-endorphin immunoreactivity. The interfering effect of contrast medium led to overestimation of the caine, valproic acid, and tobramycin were 5% or less; for quinidine, acetaminophen, and phenytoin,long-termCVs ranged from 7.2% to 8.6%.
The various procedures described (1-3) foradaptingEMIT homogeneous enzyme immunoassay procedures to the Cebaa Bio centrifugal analyzer (Roche Analytical Instruments, Inc., Nutley, NJ 07110) all extend the number of assays obtained per kit but narrow their useful analytical range. Because the relative rate of change of the differences in absorbance (M) is smaller for drug concentrations near the high end of the therapeutic range, the precision of these adapted methods is poorer in this region than with the usual EMIT protocol. We describe a procedure for use with the Cobas Bio that eliminates this difficulty.
Materials and Methods
We purchased EMIT kits from Syva Co., Palo Alto, CA 94304. Controls were prepared in our laboratory and stored at -70 "Cuntil used. EMIT buffer was reconstituted with 120 mL of type I water, rather than the recommended 150 mL. Calibrators were reconstituted according to the manufacturer's instructions. Reagents A and B were both reconstituted to twice the volume stated on each vial. Reagent A was further diluted 10-fold with EMIT buffer and used within a week. We diluted calibrators, controls, and patients' sam- 
